IP

This Week’s Life Science Headlines

February 6, 2014
/
FDA IP Litigation Medical Device News Nutritional Supplements Pharmaceuticals Product Liability Recalls Regulatory Settlements
/

Life Science Matters

Litigation

Abbott Hit with 5 AndroGel Suits in FDA Probe’s Wake (subscription required)
Pradaxa Litigation Fines Upheld, Non-Monetary Sanctions Overturned
J&J Punished for Losing Evidence in Vaginal Mesh MDL (subscription required)
Negligent Drug Design Claims May Increase in Pa. (subscription required)
9^th Circ. Urged to Reinstate Expert in Novartis Jaw Injury Suit (subscription required)
Deferred Sanctions Leave Hope for Takeda in Actos MDL (subscription required)
1^st Circ. Holds FCA Relator’s Feet to Rule 9(b) Fire (subscription required)
Biomet To

Cephalon’s Billion Dollar Patent Struck Down

Life Science Matters

On April 8, 2013, the Federal Court upheld the trial court’s judgment of invalidity and unenforceability for Cephalon’s RE’516 patent. Cephalon’s RE’516 patent used to protect their mainstay drug – Provigil®. Provigil® is the brand name for modafinil which is used to treat sleep disorders. In 2007, Cephalon, now owned by Teva Pharmaceuticals, had over $800 million in sales from Provigil®. Apotex, a generic drug manufacturer, challenged the validity and enforceability of Cephalon’s RE’516 patent, in Apotex, Inc. v. Cephalon Inc. The trial court found…
Continue reading...

Life Science Matters An inside look at the latest legal developments involving medical devices, pharmaceuticals, and more

IP

This Week’s Life Science Headlines

Cephalon’s Billion Dollar Patent Struck Down

Multicounty Litigation Order in New Jersey Provides No Guidance to Practitioners June 23, 2021

New Multicounty Litigation Application in New Jersey June 8, 2021

Lack of Agreement to Arbitrate Dooms Bid to Compel Arbitration May 26, 2021

Mixed Bag in New Jersey Medical Device Preemption Opinion May 12, 2021

First Circuit Agrees Pharmacists Provide Services, Not Sell Goods April 27, 2021